Background: Adults with hypertension often suffer from peptic ulcer disease and are more likely to receive drugs for hypertension and peptic ulcer Aim of the study: The aim of this study was to evaluate effect of L-arginine and carvedilol as nitric oxide donors on peptic ulcer and on peptic ulcer hypertension co- morbidity regarding to these parameters: blood pressure, ulcer score, ulcer index, total antioxidant capacity(TAC),nitric oxide (NO), prostaglandinE2(PGE2)and tumor necrosis factor alpha (TNF-α) Methods: Rats were classified into: Group 1: control normal group. Group 2carboxy methylcelluose(CMC) group. Group 3: peptic ulcer (PU)group, Group4: hypertension -PU group, Group 5: PU Larginine pretreated group, Group6: hypertension-PU L-arginine pretreated group, Group7: PU carvedilol pretreated group, Group8: hypertension -PU carvedilol pretreated group, Group9: hypertensionPU L-arginine treated group, Group 10: hypertension- PU carvedilol treated group Results: Treated groups showed significant improvement in all parameters related to PU and hypertension PU progression and improvement of the histopathology of stomach. Conclusion: Our study revealed that L-arginine and carvedilol showed improvement in blood pressure, ulcer score, ulcer index, TNF-α, TAC, NO and PGE2. There was no significant difference between both drugs. So our drugs have prophylactic effect against PU and hypertension PU co-morbidity and their effect appeared to be mediated, by reductions in oxidative stress and a preservation of gastro protective mechanisms as NO, PG E2 and TAC.